Runda Medical reports significant net loss and revenue decline

Shanghai Runda Medical Technology reported a net loss attributable to shareholders of RMB -162,691,533.55 for the first nine months of 2025, a significant decline compared to the previous year. The company's operating revenue for the first nine months decreased by 14.70% to RMB 5,268,459,587.79. Profit attributable to the parent company shareholders also saw a substantial year-on-year decrease of 422.64%.

The decline is primarily attributed to a challenging domestic medical policy environment, which led to reduced product prices and overall revenue. Despite these challenges, operating cash flow for the first nine months showed a positive trend, increasing by 110.54% to RMB 438,944,151.93, indicating improved operational liquidity.

Basic earnings per share for the first nine months were RMB -0.27, a decrease of 437.50% from the previous year. Total assets as of the end of the reporting period stood at RMB 13,916,199,517.14, a slight decrease of 2.72% compared to the end of the previous year.